Gastroenterology

Back to articles

New analyses of pancreatitis risk with incretin-based therapies

KEY POINT

Use of incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors was not associated with an increased risk of pancreatitis, according to a large systematic review and meta-analysis published in BMJ